The Solution Structures of Two Human IgG1 Antibodies Show Conformational Stability and Accommodate Their C1q and FcγR Ligands. by Rayner, LE et al.
1
THE SOLUTION STRUCTURES OF TWO HUMAN IgG1 ANTIBODIES SHOW
CONFORMATIONAL STABILITY AND ACCOMMODATE THEIR C1q AND FcγR 
LIGANDS
Lucy E. Rayner
1*, Gar Kay Hui
1*, Jayesh Gor
1, Richard K. Heenan
2, Paul A. Dalby
3 and Stephen J.
Perkins
1‡
*These authors contributed equally to this work.
From the
1Department of Structural and Molecular Biology, Division of Biosciences, Darwin Building,
University College London, Gower Street, London WC1E 6BT, U.K.;
2ISIS Facility, Science and
Technology Facilities Council, Rutherford Appleton Laboratory, Harwell Oxford, Didcot, OX11 0QX,
U. K.;
3Department of Biochemical Engineering, Division of Engineering, Roberts Building, University
College London, Gower Street, London WC1E 7JE, U.K.
Running Title: Solution structure of IgG1
*Address correspondence to: Prof. S. J. Perkins, Department of Structural and Molecular Biology,
Darwin Building, University College London, Gower Street, London, WC1E 6BT, U.K. Tel: 020-7679-
7048, FAX: 020-7679-7193; Email: s.perkins@ucl.ac.uk.
Keywords: Analytical ultracentrifugation, antibody, constrained modelling, neutron scattering, human
IgG1, X-ray scattering.
Background: The human IgG1 antibody
subclass is the most abundant one and is widely
used in therapeutic applications.
Results: Ultracentrifugation and X-ray/neutron
scattering, together with atomistic modelling,
revealed asymmetric concentration-
independent IgG1 solution structures.
Conclusion: The complement and receptor Fc
binding sites are not hindered by the Fab
regions, explaining its full activity.
Significance: These solution structures clarify
IgG1 activity and its therapeutic applications.
The human IgG1 antibody subclass shows
distinct properties compared to the IgG2,
IgG3 and IgG4 subclasses, and is the most
exploited subclass in therapeutic antibodies.
It is the most abundant subclass, has a half-
life as long as that of IgG2 and IgG4, binds
the  FcγR  receptor,  and  activates 
complement. There is limited structural
information on full-length human IgG1
because of the challenges of crystallisation.
To rectify this, we have studied the solution
structures of two human IgG1 6a and 19a
monoclonal antibodies in different buffers at
different temperatures. Analytical
ultracentrifugation showed that both
antibodies were predominantly monomeric,
with sedimentation coefficients s0
20,w of 6.3 S
- 6.4 S. Only a minor dimer peak was
observed,andtheamountwasnotdependent
on buffer conditions. Solution scattering
showed that the X-ray radius of gyration Rg
increased with salt concentration, while the
neutron Rg values remained unchanged with
temperature. The X-ray and neutron
distance distribution curves P(r) revealed
two peaks, M1 and M2, whose positions were
unchanged in different buffers to indicate
conformational stability. Constrained
atomistic scattering modelling revealed
predominantly asymmetric solution
structures for both antibodies with extended
hinge structures. Both structures were
similar to the only known crystal structure
of full-length human IgG1. The Fab
conformations in both structures were
suitably positioned to permit the Fc region to
bind  readily  to  its  FcγR  and  C1q  ligands 
without steric clashes, unlike human IgG4.
Our molecular models for human IgG1
explain its immune activities, and we discuss
its stability and function for therapeutic
applications.
IgG1 is the most abundant human IgG antibody
subclass (8 mg/ml) of the four found in serum.
Following high specificity and affinity binding
of the antigen to their Fab regions, the immune2
response and effector functions are mediated
through the Fc region. IgG1 binds to every class
of  Fcγ  receptor  (FcγR)  found  on  immune 
effector cells, and activates the complement
cascade when C1q is recruited by several Fc
regions (1). Binding to FcγRs on immune cell 
surfaces leads to diverse immune responses,
including antibody-dependent cell-mediated
cytotoxicity, to clear foreign antigen from the
body. IgG1 has been extensively studied,
making it the most understood and exploited
human IgG subclass for the development of
therapeutic antibodies. Over thirty IgG
monoclonal antibodies have been approved as
of June 2012 for clinical use by the Food and
Drug Administration, of which 68% of
marketed and late-stage clinical phase
therapeutic antibodies involve the human IgG1
subclass (2).
The four human IgG subclasses IgG1-IgG4
vary primarily in the hinge region, which
connects the Fab and Fc regions together, and
contributes flexibility at these central regions.
The hinge length is linked with IgG
functionality. The hinge is best considered as a
three-part structure, in which the upper and
middle hinge sections of IgG1, IgG2, IgG3 and
IgG4 contain 15, 12, 62 and 12 amino acids
respectively. The order of flexibility is IgG3 >
IgG1 > IgG4 > IgG2 which correlates well with
the hinge length (3,4). The upper hinge
determines the arrangement between the two
Fab regions and mediates flexibility and
reorientations of each Fab arm; this allows
IgG1 to bind to multiple antigens in different
positions (5).Two cysteineresidues (Cys
226 and
Cys
229) in the middle hinge form interchain
disulphide bonds between the two heavy chains
to join these together (Fig. 1). The lower hinge
is responsible for the flexibility and positioning
of the Fc region relative to the Fab arms and
affects the binding of Fc to FcγR (5,6). 
Only limited structural information is available
for full-length IgG antibodies. These are
difficult to crystallise for reason of the flexible
domain arrangements found in IgG. Thus
hinge-deleted human IgG1 structures solved by
X-ray crystallography include IgG1 Dob and
Mcg (7-9). These revealed symmetric IgG
structuresthatarenotatrue pictureofwild-type
antibody conformations. The crystal structure
of a full-length human IgG1 b12 has been
reported alongside full-length murine IgG1 and
IgG2a (10-12). Human IgG1 b12 showed an
asymmetric structure with extended hinges,
although atomic coordinates for part of one of
the hinge regions is missing. These crystal
structures necessarily contain IgG held in a
fixedpositionbyintermolecularcontactswithin
the crystallographic unit cell, offering only a
single snapshot of the multiple conformations
expected in solution (13). The advent of
atomistic constrained scattering modelling has
mitigated this issue. Thus human IgG4, IgA1
and IgA2, IgD and IgM have been studied
successfully in physiological buffers, and
molecular structures have been determined in
Protein Data Bank coordinate formats (14-19).
SolutionstructuresforthehumanIgG1subclass
are essential to understand its function and
stability in the human body, especially for
therapeutic applications. Joint X-ray and
neutron scattering studies rectify the limitation
of the single available IgG1 b12 crystal
structure by enabling the study of different
buffer and solution conditions on the IgG1
structure. The recent advent of high-throughput
X-ray measurements provides hundreds of
scattering curves in a single measurement
session, and these permit atomistic antibody
structures to be determined for a broad range of
solution conditions. Here we report solution
structures for two IgG1 antibodies, IgG1 6a and
IgG1 19a, with known sequences (Fig. 2). Both
IgG1 were found to be predominantly
monomeric in all buffer conditions tested. Both
IgG1 solution structures displayed semi-
extended asymmetric arrangements of the Fab
regions relative to the Fc region. These
structures become more elongated with
increase in salt concentration. By reference to
the crystal structure of a FcγR-Fc complex and 
a docked structural model for C1q binding to
Fc, it could be assessed whether the Fab regions
in both IgG1 solution structures allowed
enough space for the FcγR and C1q ligands to 
bind to the top of the Fc region in IgG1. The
successful outcome of our analyses accounted
for the reactivity of IgG1 for FcγR and C1q. 
This is in marked distinction to our recent
similar analyses for human IgG4, where this
binding to the Fc region was most likely
sterically hindered by the Fab regions (15).
Previously, conformational instabilities were
found in IgG4 (15); it is therefore also crucial
to identify whether or not IgG1 is also affected
by the same instabilities that occur in IgG4.3
EXPERIMENTAL PROCEDURES
Purification and composition of IgG1 - Both
IgG1 6a and IgG1 19a were generously
supplied by Dr Bryan Smith at UCB
(https://www.ucb.com). Immediately prior to
measurements, both were further purified by
gel filtration to remove non-specific aggregates
using a Superose 6 10/300 column (GE
Healthcare), then concentrated using Amicon
Ultra spin concentrators (50 kDa molecular
mass cut-off), and dialyzed at 4°C against the
appropriate ultracentrifugation and scattering
buffer (see below). The sequence identity for
the two IgG1 molecules was 100 % for the CH1,
CH2, CH3 and CL domains. Differences in
sequences were foundin the VH (65.2%)and VL
(73.2%) domains. Total sequence identity
between the two IgG1 forms was 88.7% (Fig.
2). The N-linked oligosaccharides at Asn
297 on
the CH2 domains (Fig. 2) were assumed to have
a typical complex-type biantennary
oligosaccharidestructurewithaMan3-GlcNAc2
core and two NeuNAc.Gal.GlcNAc antennae
(20). The IgG1 6a molecular mass was
calculated to be 150.1 kDa, its unhydrated
volume was 193.1 nm
3, its hydrated volume
was 254.4 nm
3 (based on a hydration of 0.3g of
water per gram of glycoprotein and an
electrostricted volume of 0.0245 nm
3 per bound
water molecule), its partial specific volume v
was 0.729 ml/g, and its absorption coefficient at
280 nm was 15.4 (1%, 1 cm path length) (21).
Likewise, IgG1 19a has a calculated molecular
mass of 149.7 kDa, an unhydrated volume of
192.4 nm
3, a hydrated volume of 253.5 nm
3, a v
of 0.728 ml/g and an absorption coefficient at
280 nm of 15.6 (1%, 1 cm path length).
All data were recorded in phosphate-buffered
saline with different NaCl concentrations. That
termed PBS-137 has a composition of 137 mM
NaCl, 8.1 mM Na2HPO4, 2.7 mM KCl and 1.5
mM KH2PO4 (pH 7.4). When 137 mM NaCl
was replaced by 50 mM NaCl or 250 mM NaCl,
these were termed PBS-50 or PBS-250,
respectively. The buffer densities were
measured using an Anton Paar DMA 5000
density meter, and compared with the
theoretical values calculated by SEDNTERP
(22). This resulted in densities of 1.00530 g/ml
for PBS-137 at 20°C (theoretical, 1.00534
g/ml), 1.00189 g/ml for PBS-50 at 20°C
(theoretical, 1.00175 g/ml), 1.01003 g/ml for
PBS-250 at 20°C (theoretical, 1.00998 g/ml)
and 1.11238 g/ml for PBS-137 at 20°C in 100%
2H2O.
Sedimentation velocity data for IgG1 -
Analytical ultracentrifugation data for IgG1 6a
were obtained on two Beckman XL-I
instruments equipped with AnTi50 rotors.
Sedimentation velocity data were acquired for
IgG1 samples in PBS-50, PBS-137 and PBS-
250 at 20°C (H2O) and in PBS-137 with 100%
2H2O. Sedimentation velocity data were
acquired for IgG1 19a only in PBS-137 (H2O)
at 20°C. Data were collected at rotor speeds of
40,000 rpm and 50,000 rpm in two-sector cells
with column heights of 12 mm. Sedimentation
analysis was performed using direct boundary
Lamm fits of up to 745 scans using SEDFIT
(version 14.1) (23,24). SEDFIT resulted in
size-distribution analyses c(s) that assume all
species to have the same frictional ratio f/f0. The
final SEDFIT analyses used a fixed resolution
of 200 and optimized the c(s) fit by floating f/f0
and the baseline until the overall root-mean-
square deviations and visual appearance of the
fits were satisfactory. The percentage of
oligomersinthetotalloadingconcentrationwas
derived using the c(s) integration function.
X-ray and neutron scattering data for IgG1 - X-
ray scattering data were obtained during a beam
session in 16-bunch mode on Instrument ID02
at the European Synchrotron RadiationFacility,
Grenoble, France, operating with a ring energy
of 6.0 GeV on the Beamline ID02 (25). Data
were acquired using a fast readout low noise
camera (FreLoN) with a resolution of 512×512
pixels. A sample-to-detector distance of 3.0 m
was used. Both IgG1 6a and IgG1 19a were
studied in PBS-50, PBS-137 and PBS-250 at
20°C. IgG1 6a was studied at four
concentrations between 0.5-2.0 mg/ml for each
condition, and also at 4 mg/ml in PBS-137.
IgG1 19a was studied at six concentrations
between 0.22-1.35 mg/ml in PBS-50, between
0.30-1.89 mg/ml in PBS-137 and between 0.26-
1.62 mg/ml in PBS-250. Sample volumes of
100  μl  were  measured  in  a  polycarboxylate 
capillary of diameter 2 mm that avoids protein
deposits during exposures, with the sample
being moved continuously during beam
exposure to reduce radiation damage. Sets of 10
time frames, with a frame exposure time of 0.1
s or 0.2 s each, were acquired in quadruplicate
as a control of reproducibility. Online checks
during data acquisition confirmed the absence4
of radiation damage, after which the 10 frames
were averaged.
Neutron scattering data were obtained on
Instrument SANS2D at the ISIS pulsed neutron
source at the Rutherford Appleton Laboratory,
Didcot, UK (26). A pulsed neutron beam was
derived from proton beam currents of ~40 μA. 
SANS2D data were recorded with 4 m of
collimation, a 4 m sample-to-detector distance,
a12mmbeamdiameterandawavelengthrange
of 0.175 - 1.65 nm made available by time-of-
flight. Samples were measured in 2 mm path
length circular banjo cells for 1-2 h in a
thermostated rack at 6°C, 20°C and 37°C. Data
were only collected for IgG1 6a at three
concentrations between 2.0-4.0 mg/ml in PBS-
137 in 100%
2H2O.
In a given solute–solvent contrast, the radius of
gyrationRgisa measureofstructuralelongation
if the internal inhomogeneity of scattering
densities within the protein has no effect.
Guinier analyses at low Q (where Q = 4π sin 
θ/λ; 2θ is the scattering angle and λ is the
wavelength) gives the Rg and the forward
scattering at zero angle I(0) (27):
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This expression is valid in a Q.Rg range up to
1.5. If the structure is elongated, the mean
radius of gyration of cross-sectional structure
Rxs and the mean cross-sectional intensity at
zero angle [(I(Q)Q]Q→0 is obtained from:
ொ⟶଴
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The cross-sectional plot for immunoglobulins
exhibits two distinct regions, a steeper
innermost one and a flatter outermost one (28),
identified by Rxs-1 and Rxs-2, respectively. The Rg
and Rxs analyses were performed using an
interactive PERL script program SCTPL7 (J. T.
Eaton and S. J. Perkins, unpublished software)
on Silicon Graphics OCTANE Workstations.
Indirect Fourier transformation of the scattering
data I(Q) in reciprocal space into real space to
give the distance distribution function P(r) was
carried out using the program GNOM (29):
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P(r) corresponds to the distribution of distances
r between volume elements. This provides the
maximum dimension of the antibody L and its
most commonly occurring distance vector M in
real space. For this, the X-ray I(Q) curve
utilized up to 365 data points in the Q range
between 0.09 nm
-1 and 1.70 nm
-1. The neutron
I(Q) curve utilized up to 45 data points in the Q
range between 0.18 nm
-1 and 1.5 nm
-1.
Debye scattering and sedimentation coefficient
modelling of IgG1 - A total of 20,000
conformationally randomised human IgG1
models were created by joining the IgG1 Fab
and Fc structures with conformationally
randomised hinge peptides. The crystal
structure of human IgG1 b12 (PDB code
1HZH) was used for this (10). This IgG1
structure has complete heavy chains (H and K)
and light chains (L and M), with the exception
ofthirteenmissingKchainresidues,namely the
Fab CH1 residues
132SKSTSGG
138, the core
hinge residues
223THT
225 and the Fc CH3 C-
terminus
445PGK
447 (10). IgG1 b12 has high
sequenceidentity toIgG16aandIgG119a(Fig.
2). Most of the sequence differences occur in
the VH and VL domains where antigen binding
occurs. Additionally, small sequence
differences in the CH1 and CH3 domains result
from allotypic differences. Human IgG1 has
four allotypes (G1m1, G1m2, G1m3 and
G1m17) which may be expressed in IgG1 as
G1m3, G1m17,1 or G1m17,1,2 heavy chains
(30). IgG1 b12 is the G1m17,1 allotype with
Lys
214 in the CH1 domain (Fig. 2D) and Asp
356
and Leu
358 in the CH3 domain (Fig. 2G).
Additionally, IgG1 b12 has Ala
215 in place of
the wild type Val
215; this is not an allotypic
difference and may have been engineered
during the antibody production. IgG1 6a and
19a are both Gm3 allotypes with Arg
214 in the
CH1 domain (Fig. 2D) and Glu
356 and Met
358 in
the CH3 domain (Fig. 2G). The light chain
subclass  can  be  either  κ  or  λ.  While  the  κ 
subclass has only one gene copy, there can be
7-11  gene  copies  of  λ  depending  on  the 
haplotype (30). The κ light chain subclass has 
three allotypes (Km1, Km2, Km3), while the λ 
light chain subclasses have no serologically
defined allotypes. The κ light chain allotypes 
may be expressed as Km1, Km1,2 or Km3.5
IgG1 b12, IgG1 6a and IgG1 19a all have the
Km3 allotype with Ala
159 and Val
197 in the CL
domain (Fig. 2B). IgG1 b12 shows a sequence
difference of Arg
208 in the CL domain (Fig. 2B),
which is not an allotypic difference, and may
have been engineered. The unhydrated volumes
of IgG1 b12, IgG1 6a and IgG1 19a were
calculated as 194.3 nm
3, 193.1 nm
3 and 192.4
nm
3 respectively. The volume similarity was
within acceptable limits to allow the use of
IgG1 b12 as a model for the IgG1 6a and IgG1
19a modelling searches.
In order to generate conformationally
randomised trial IgG1 models for scattering
fits, four sets of 5,000 models were created,
each using different hinges sampled
independently at random. Conformational
randomisation of the hinges was achieved using
moleculardynamicsintheDiscoverymoduleof
the molecular modelling software Insight II
(Accelrys) on Silicon Graphics OCTANE
workstations. To create the first two sets of
asymmetric models, a hinge peptide
220CDKTHTC
226 was constrained to be of
minimum lengths either between 1.72 nm to
2.33 nm, or between 2.33 nm to 2.45 nm (where
the latter is almost fully extended in length). As
residue Cys
220 is located asymmetrically in
relation to the Fc structure, all the created
models were asymmetric. Cys
220 and Cys
226
were used as anchor points because they
connect the Fab heavy and light chains in a
disulphide bridge. To create two more sets of
asymmetric and symmetric models, a
nineteen-residue hinge peptide
220CDKTHTCPPCPAPELLGGP
238 was
constrained with minimum lengths either
between 4.66 nm and 6.32 nm, or between 6.32
and 6.65 nm (where the latter is almost fully
extended in length) in order to avoid
abnormally short hinge structures. As residue
Pro
238 was located symmetrically in the Fc
structure, the resulting models contained Fab
arms in both symmetric and asymmetric
orientations about the Fc region. The outermost
two residues were anchor points for the
superimposition of each hinge conformation
onto the Fab and Fc structures in order to create
the full IgG1 model.
The X-ray or neutron scattering curve was
calculated from each IgG1 model using sphere
models for comparison with the experimental
IgG1 curves. A cube side of 0.541 nm in
combination with a cut-off of four non-
hydrogen atoms was used to convert the atomic
coordinates into 1220 spheres that
corresponded to the unhydrated structure seen
by neutron scattering in
2H2O. Because
hydration shells are visible by X-rays, a
hydration shell corresponding to 0.3 g of water
per gram of protein was created using HYPRO
(31), giving an optimal total of 1607 spheres.
The X-ray scattering curve I(Q) was calculated
using the Debye equation adapted to spheres
(16,32). Steric overlap between the Fab and Fc
regions was assessed using the number of
spheresnineachmodel,wheremodelsshowing
less than 95% of the required total of 1607
spheres (X-ray) or 1220 spheres (neutrons)
were discarded. Of the 20,000 models, 86%
showed no steric overlap. Next, the X-ray Rg,
Rxs-1 and Rxs-2 values were calculated from the
modelled curves in the same Q ranges used for
the experimental Guinier fits. Models that
passed Rg and Rxs filters of ± 5% of the
experimental value were then ranked using a
goodness-of-fit R-factor (defined by analogy
with protein crystallography) calculated in the
Q range extending to 1.7 nm
-1. For the neutron
modelling of IgG1 6a, the unhydrated sphere
models were used to calculate the scattering
curves. Of the 20,000 models, 91% showed no
stericoverlap.Themodelscreatedfromneutron
scattering were assessed as for the X-ray
scattering models above, following corrections
for wavelength spread and beam divergence,
but no correction was required for a flat
background caused from incoherent scattering.
Sedimentation coefficients s
0
20,w were
calculated directly from the hydrated Debye
spheremodelsusingtheprogramHYDRO(33).
They were also calculated from the atomic
coordinates in the HYDROPRO shell
modelling program using the default value of
0.31 nm for the atomic element radius for all
atoms to represent the hydration shell (34).
Previous applications of these calculations to
antibodies are reviewed elsewhere (35).
To assess the fit searches, the distances d1, d2
and d3 were determined from the centers-of-
mass of the Fab and Fc regions (excluding
hydrogen atoms) using a Python script. The
three angles between the Fab and Fc regions
were defined in a Python script as the angle of
intersection from the dot product between two
vectors. Each vector was the long axis through6
each Fab or Fc region, each defined as the line
passing through the centres of gravity between
each cluster of four cysteine α-carbon atoms at 
the two ends of the Fab and Fc regions (one
cluster at each end of each Fab or Fc region,
corresponding to the conserved disulphide
bridge in each immunoglobulin fold domain).
Artwork was prepared using PyMOL
(Schrödinger, LCC). Superimpositions of the
Fc region were performed using the align
function within PyMOL. To dock the Fc region
with the C1q head, the web server algorithm
PatchDock (version beta 1.3) (36) was used in
order to take advantage of its ability to include
specified residues as potential binding sites. Its
output was refined using FireDock from the
same web site (37).
Protein Data Bank accession numbers – The
three sets of 10 best-fit models are currently
available as supplemental material. They have
been deposited in the Protein Data Bank under
accession codes 4QOU (IgG1 6a by X-rays in
PBS-137), 4QOV (IgG1 19a by X-rays in PBS-
137) and 4QOW (IgG1 6a by neutrons in PBS-
137).
RESULTS
Purification of IgG1 - Both IgG1 6a and IgG1
19a were subjected to gel filtration to ensure
that the protein was monodisperse immediately
prior to ultracentrifugation or scattering
experiments. Both molecules eluted as a
symmetric main peak at approximately 15.5 ml
(Fig. 3), and showed a single band between 200
and 116 kDa in non-reducing SDS-PAGE that
corresponds to the expected masses of 150.1
kDa and 149.7 kDa for intact IgG1 6a and IgG1
19a respectively. Under reducing conditions,
the heavy chains for both IgG1 molecules were
observed at an apparent molecular mass of
55 kDa, and the light chains were observed
between 31 and 21.5 kDa, both as expected
(Fig. 3).
Analytical ultracentrifugation of IgG1 -
Sedimentation velocity experiments examined
the size and shape of IgG1 6a at concentrations
between 0.2-4 mg/ml, and IgG1 19a between
0.5-2.24 mg/ml. The SEDFIT analyses
involved fits of as many as 745 scans, and the
good agreement between the experimental
boundary scans and fitted lines is clear (Fig. 4).
A major monomer peak was observed at s20,w
values of 6.4 S for IgG1 6a and 6.3 S for IgG1
19a. These s20,w values are consistent with the
rangeofvaluesof6.3–6.8Spreviously reported
for human IgG1 (38,39,40). Both IgG1 6a and
IgG1 19a were predominantly monomeric in
solution, and accompanied by a minor dimer
peak.
From the c(s) analyses, the molecular masses of
the monomer peak for IgG1 6a were reported as
153kDa(PBS-50),146kDa(PBS-137)and149
kDa (PBS-250) in light water, and 164 kDa
(PBS-137 at 20°C) inheavy water. These agree
well with the composition-calculated mass of
150 kDa. The molecular mass of the IgG1 19a
monomerpeakwasmeasuredas161kDa(PBS-
137) in light water, also in agreement with the
composition-calculated mass of 150 kDa.
The apparent sedimentation rates of the IgG1
monomer were independent of sample
concentration or rotor speed (Fig. 5A).
Extrapolation of the corrected s20,w values to
zero concentration gave monomer s
0
20,w values
of 6.42 S for IgG1 6a for 40,000 r.pm., which is
similar to that of 6.44 S for 50,000 rpm (PBS-
137 at 20°C). For IgG1 19a, the monomer s
0
20,w
valuewas6.34Sforbothrotorspeedsof40,000
and 50,000 rpm (PBS-137 at 20°C). All other
data reported in this study are for 40,000 rpm.
No change in s
0
20,w value was observed at
different buffer conditions, with IgG1 6a giving
s
0
20,w values of 6.42 S, 6.42 S and 6.35 S for
PBS-50, PBS-137 and PBS-250 respectively in
lightwater(Fig.5A).IgG16ameasuredinPBS-
137 in heavy water gave an apparent
sedimentation of 3.92 S (Fig. 4B). When
corrected for the buffer density and viscosity of
heavy water, a s
0
20,w value of 7.01 S was
obtained. Given that the partial specific volume
v for proteins is affected by the hydration shell
(21,33), and that the hydration shell for heavy
water has a higher mass than that for light
water, the v values will be reduced in 100%
2H2O. When the v value of 0.715 ml/g was used
for 20°C in place of 0.728 ml/g, this gave s
0
20,w
values similar to that of PBS-137 in light water
of 6.47 S (Fig. 5A). For IgG1 19a in light water,
the s
0
20,w value of 6.34 S for PBS-137 at 20°C
was similar to that of IgG1 6a. This outcome
indicates their similar overall shapes.
The c(s) analyses for IgG1 6a revealed a minor
dimer peak at s
0
20,w values between 9 S and 10 S
in the size-distribution analyses c(s) (Figs. 4
and 5). The molecular masses of the dimer peak7
in light water were 263 ± 4 kDa (PBS-50), 260
± 10 kDa (PBS-137), 257 ± 5 kDa (PBS-250),
and 286 ± 9 kDa (PBS-137 in heavy water).
These masses are comparable with the expected
value of 300 kDa for the IgG1 dimer. The IgG1
6a dimer s
0
20,w values in light water were 9.21 ±
0.1 S (PBS-50), 9.69 ± 0.38 S (PBS-137) and
9.12 ± 0.07 S (PBS-250) at 20°C. That in heavy
water was similar at 9.35 ± 0.09 S for PBS-137.
Similarly, IgG1 19a showed a small dimer peak
with a s
0
20,w value of 8.8 ± 0.3 S in PBS-137 at
20°C and a molecular mass of 266 ± 9 kDa in
light water. This also agreed well with the
predicted mass of 300 kDa for its dimer.
Integration of the monomer and dimer c(s)
peaks showed that the amount of dimer did not
alter with sample concentration or buffer
composition, with the majority of samples
showing less than 5% dimer for both IgG1 6a
and IgG1 19a (Fig. 5B).
X-ray and neutron scattering of human IgG1 -
The solution structure of IgG1 was jointly
analysed by both X-ray and neutron scattering
for reason of reproducibility. X-rays in light
water buffers monitor the hydration shell as
well as the protein structure, while neutrons in
heavy water buffers do not see this hydration
shell.
X-rays were most effective for looking at IgG1
at 20°C in three different NaCl concentrations.
Data collection of IgG1 6a was carried out
between 0.5 and 4 mg/ml, using time-frame
analyses to ensure the absence of radiation
damage effects. Guinier analyses resulted in
high-quality linear plots and revealed three
distinct regions of the I(Q) curves, as expected
for antibodies, from which the Rg, Rxs-1 and Rxs-
2 values were obtained within satisfactory Q.Rg
and Q.Rxs limits (Fig. 6A; Table 1). The X-ray
Rg values for IgG1 6a in PBS-50, PBS-137 and
PBS-250 showed no concentration dependence
with mean values of 5.17 nm, 5.19 nm and 5.32
nm respectively (Fig. 7A). There was a slight
increase in Rg with salt concentration, most
notably with PBS-250. The I(0)/c values for
IgG1 6a also showed no concentration
dependence (Fig. 7A). Each of the Rxs-1 and Rxs-
2 values were unchanged between PBS-50,
PBS-137 and PBS-250, with a mean Rxs-1 value
of 2.62 nm, 2.64 nm and 2.65 nm, respectively,
and a mean Rxs-2 value of 1.43 nm, 1.43 nm and
1.42 nm, respectively. IgG1 19a was studied
between 0.22 and 1.89 mg/ml in the same
buffers as IgG1 6a (Fig. 6C). The X-ray Rg
values showed no concentration dependence
with mean values of 5.10 nm, 5.22 nm and 5.32
nm in PBS-50, PBS-137 and PBS-250
respectively (Fig. 7C). As for IgG1 6a, there
was a slight increase in Rg with increasing NaCl
concentration. Similarly, the I(0)/c values for
IgG1 19a showed no concentration dependence
(Fig. 7C). Each of the Rxs-1 and Rxs-2 values were
unchanged between PBS-50, PBS-137 and
PBS-250, with a mean Rxs-1 value of 2.63 nm,
2.60 nm and 2.65 nm, respectively, and a mean
Rxs-2 value of 1.48 nm, 1.42 nm and 1.50 nm,
respectively (Fig. 7C). The X-ray Rg, I(0)/c, Rxs-
1 and Rxs-2 values for IgG1 19a were in
agreement with IgG1 6a.
Neutron scattering viewed the unhydrated
protein structure in which the hydration shell is
almost invisible in heavy water (33). Neutrons
were most useful for temperature studies in
PBS-137, as temperature-dependent conditions
were less accessible by X-ray scattering. IgG1
6a in 100%
2H2O buffer was analysed between
2.0-4 mg/ml. The Guinier analyses revealed
high-quality linear fits for the same three Rg,
Rxs-1 and Rxs-2 parameters as for X-rays (Fig.
6B). The neutron Rg values remained
unchanged with concentration at 6°C, 20°C and
37°Cwithmeanvaluesof5.18nm,5.10nmand
5.13 nm respectively (Fig. 7B). These Rg values
were similar to those for X-ray scattering. The
corresponding I(0)/c values also remained
unchanged (Fig. 7B). The neutron Rxs-1and Rxs-2
values showed no concentration dependence
between 6°C, 20°C and 37°C with mean Rxs-1
values of 2.48 nm, 2.43 nm and 2.46 nm
respectively, and mean Rxs-2 values of 1.25 nm,
1.25 nm and 1.20 nm, respectively (Fig. 7B).
The neutron Rg, Rxs-1 and Rxs-2 values were
slightly smaller than the corresponding X-ray
values, in particular for the two Rxs values, and
this reduction is attributed primarily to the near
invisibility of the surface hydration shell in
heavywater,aswellasthehighnegativesolute-
solvent contrast difference which will also
reduce these values (33).
The distance distribution function P(r) provides
structural information on IgG1 in real space,
namely its overall length and the separation
between its Fab and Fc regions. The X-ray P(r)
analyses gave Rg values for IgG1 that were
similar to those from the X-ray Guinier
analyses, showing that the two analyses were8
self-consistent (filled and open symbols in Fig.
7A). The maximum length L of IgG1 6a was
determined from the value of r when the P(r)
curve intersects zero to be 16 nm for PBS-50,
PBS-137 and PBS-250 (Fig. 8A). The maxima
in the P(r) curves correspond to the most
frequently occurring interatomic distances
within the structure. For IgG1 6a, two peaks,
M1 and M2, were identified in all the P(r)
curves at approximately 4 nm and 7.5 nm
respectively. The M1 peak corresponds mostly
to distances within each Fab and Fc region,
while the M2 peak corresponds mostly to
distances between pairs of Fab and Fc regions.
No buffer dependence in the positions of peaks
M1 and M2 was observed (Fig. 9A). Because
M2 is unchanged, the averaged separation
between the Fab and Fc regions within IgG1
remains unchanged in 50-250 mM NaCl. This
finding differs from that for IgG4 which
showed a concentration dependence of M2
below 2 mg/ml (14,15). IgG1 19a showed two
M1 and M2 peaks at similar values of ~4 nm
and ~8 nm respectively (Fig. 9C). IgG1 19a
exhibits the same L value of 16 nm as IgG1 6a
in PBS-137 and PBS-250. However, the length
of IgG1 19a in PBS-50 is slightly reduced at 15
nm (Figs. 8C and 9C).
The neutron P(r) analyses of IgG1 6a in heavy
water showed that the Rg values for IgG1 6a at
6°C, 20°C and 37°C did not change with
increasing concentration nor temperature (Fig.
7B). The neutron L values were 16 nm at 6°C,
20°C and 37°C (Fig. 8B). The two peaks M1
and M2 were again identified at approximately
4 nm and 7 nm respectively in the neutron P(r)
curves (Fig. 8B). The positions of M1 and M2
were unchanged with concentration, in
agreement with the X-ray P(r) data.
Starting model for the human IgG1 scattering
fits - The starting model for scattering fits of
IgG1 was the crystal structure of human IgG1
b12 (10). The full hinge is formally defined by
the twenty-three residues
216EPKSCDKTHTCPPCPAPELLGGP
238 (3,5)
in which the Fab region formally ends at Val
215
and the Fc region starts at Ser
239 (Fig. 1). The
IgG1 hinge contains six Pro residues and two
interchain disulphide bridges at Cys
226 and
Cys
229. The asymmetric modelling considered
only the upper hinge
220CDKTHTC
226 with
Cys
220 and Cys
226 acting as tethers. As this
hinge is located asymmetrically relative to the
Fc region, these 10,000 models do not have 2-
fold symmetry. Only one of the inter-chain
disulphide bonds is intact at Cys
226. The
symmetric modelling considered the upper,
middle and lower hinge and this resulted in a
19-residue peptide
220CDKTHTCPPCPAPELLGGP
238. Because
the two Pro
238 residues were located in the
middle of the Fc region, this approach
generated both symmetric and asymmetric
models. For these 10,000 further models, the
Cys
226 and Cys
229 inter-chain disulphide bonds
were not explicitly intact.
Conformational searches for the human IgG1
solution structure - In order to model both the
IgG1 6a and IgG1 19a solution structures,
20,000 conformationally-randomized IgG1
structures were created by connecting the Fab
and Fc structures to one of four libraries of
conformationally-randomizedhingepeptidesof
lengths 1.72-2.33 nm and 2.33-2.45 nm
(asymmetric) and 4.66-6.32 nm and 6.32-6.65
nm (symmetric) (Experimental Procedures).
Each modelled scattering curve was compared
with the experimental X-ray and neutron
scattering curves. To test a broad range of
solution conditions, the six modelled X-ray
curves were IgG1 6a at the highest available
concentrations of 2 mg/ml, 4 mg/ml and 2
mg/ml in PBS-50, PBS-137 and PBS-250
respectively, plus IgG1 19a at the highest
available concentrations of 1.4 mg/ml, 1.9
mg/ml and 1.6 mg/ml in PBS-50, PBS-137 and
PBS-250 respectively. As previous (15), the
occurrence of 4% dimer was assumed to have
little effect on the scattering modelling. The
modelled neutron curve for IgG1 6a was the
highest concentration of 4 mg/ml in PBS-137 at
20°C in heavy water. The seven fit analyses
were assessed in R-factor vs. Rg graphs (Fig.
10A-C). In all seven analyses, the occurrence of
a single clear minimum in the R-factor values
identified a single conformational family of
solution structures for IgG1 starting from a
wide range of trial orientations and translations
of the two Fab and Fc regions. The lowest
R-factors in the 20,000 curve fits corresponded
to modelled Rg values that were close to the
experimental Rg values as desired.
Filters based on the experimental scattering
data were used for all 20,000 models to reject
unsatisfactory models and identify the ten best-
fit models for each search:9
(i) A ± 5% filter for steric overlap eliminated
models in which the Fab and Fc regions
sterically overlapped with each other due to
inappropriate hinge conformations used in
modelling. In order to match the composition-
calculated volume of IgG1, sphere models
needed a minimum number N of 1607 spheres
forthehydratedX-ray modelsand1220spheres
for the unhydrated neutron models.
(ii) A ± 5% filter for the modelled Rg values
(calculated from the same Guinier Q ranges
used for the experimental analyses) identified
the models that agreed best with the
experimental X-ray or neutron Rg values.
(iii) The models that passed the N and Rg filters
were arrangedin orderoftheirlowestR-factors.
The resulting ten best-fit models for IgG1
occurred as a single cluster at the R-factor
minimum in each of the seven searches (green
in Fig. 10A-C), indicating a single best-fit
solution structure.
Only one of the inter-chain disulphide bonds at
Cys
226 was conserved in the asymmetric
models. For the symmetric models, the pairs of
two Cys
226 and two Cys
229 residues may not be
proximate in the best-fit models, because the
disulphide bridges were not preserved in the
libraries. In the ten best-fit models, the α-carbon 
separations were 0.56-1.49 nm for Cys
226 and
1.14-1.55 nm for Cys
229 in IgG1 6a by X-rays,
0.56-3.63 nm for Cys
226 and 1.55-3.52 nm for
Cys
229 in IgG1 19a by X-rays, and 0.56 nm for
Cys
226 and 1.55 nm for Cys
229 for IgG1 6a by
neutrons.  These  α-carbon  separations  were 
comparable with an expected separation of 0.4-
0.75 nm between two bridged Cys residues
(41), showing that the best-fit IgG1 models
were compatible with disulphide-bridged
hinges.
The best-fit modelled curves showed good
visual fits in all seven cases with the
experimental curves (Fig. 11A-C). In most
cases, the Rg values for the ten best-fit models
were within error of the experimental values
(Table 1). The seven sets of models (Fig. 12A-
C) generally displayed asymmetric
arrangements of the two Fab regions compared
to the Fc region. Both IgG1 6a and IgG1 19a
showed mostly asymmetric structures, although
a few symmetric structures were observed for
IgG1 6a in PBS-137 and IgG1 19a in PBS-250.
In summary, both IgG1 6a and IgG1 19a
appeared to exhibit a T-shaped arrangement in
PBS-50 and a Y-shaped arrangement in PBS-
250 with intermediate T- and Y-shaped
structures in PBS-137 (Fig. 12A,C). This shape
difference would account for the slightly
increased Rg values seen in high salt. Surveys of
the distances between the centres of the Fab and
Fc regions in the best fit IgG1 6a X-ray and
neutron models and IgG1 19a X-ray models
showed similar distributions (Fig. 13). The
X-ray R-factor values for the best-fit IgG1
models (pink in Fig. 10A,C) were acceptable at
3.0-3.1%, for IgG1 6a and 2.8-3.7% for IgG1
19a(Table1).Theneutron R-factorvalueswere
acceptable at 2.6-2.7% (pink in Fig. 10B).
These R-factor values compare well with those
from other similar modelling fits (35).
Sedimentation coefficient modelling of human
IgG1 - The s
0
20,w values of the best-fit X-ray
hydrated IgG1 models were calculated for
comparison with the average experimental
valuesof6.42SforIgG16aand6.34SforIgG1
19a (Fig. 5). For the best-fit hydrated sphere
models, the s
0
20,w values were 6.67-6.82 S and
6.63-6.90 S for IgG1 6a and IgG1 19a
respectively using HYDRO (Table 1). The
corresponding s
0
20,w values using HYDROPRO
were 6.37-6.73 S and 6.37-6.68 S for IgG1 6a
and IgG1 19a respectively (Table 1). Given that
the calculations should be accurate to within ±
0.21 S (35), the modelled s
0
20,w values agree
well with the experimental values.
DISCUSSION
The availability of abundant X-ray scattering
data for two IgG1 molecules in three buffers
permitted a detailed appraisal of the solution
structure of human IgG1 and its comparison
with the less stable IgG4 solution structure.
These experiments were supported by
complementary neutron scattering and
ultracentrifugation experiments. The data sets
enabled atomistic conformational analyses that
resulted in seven independent determinations of
an asymmetric IgG1 solution structure (Fig.
12A-C). The combination of these IgG1
solution structures with a docking model for the
interaction between human IgG1 Fc and the
crystal structure of the C1q globular head
(42,43), and the crystal structure of the human
Fc-FcγR receptor (44) show that the Fc region 
of human IgG1 is exposed and enables this to
reactreadily withitstwo majoreffectorligands,
unlike human IgG4 (15).10
IgG1 has the highest IgG serum concentration
of the four IgG subclasses IgG1 to IgG4 at an
average level of 8 mg/ml (in a range of 5–12
mg/ml), comprising approximately 60-70 % of
the total IgG in normal adult serum (1). IgG1-
IgG4 have different heavy chain isotypes which
primarily differ in the hinge region (Fig. 2H).
IgG1 activates complement-mediated lysis via
C1q binding in the complement classical
pathway,andbindstoallthreeclassesofhuman
Fcγ receptors FcγRI, FcγRII and FcγRIII. IgG1 
has  different  affinities  for  the  FcγRI,  FcγRII 
and FcγRIII, and its binding to different FcγRs 
on different immune cells result in different
immune responses including antibody-
dependent cell-mediated cytotoxicity, pro-
inflammatory cytokine production and
phagocytosis (45). The precise role of the four
IgG subclasses in the immune response is
unclear. A recent temporal model suggests that
the different properties of the IgG subclasses,
their concentrations and their emergence at
different stages facilitate a more cohesive
immune response (46). An understanding of the
distinct properties of the IgG subclasses is
desired; we now have complete scattering
analyses for human IgG1 and IgG4.
Solution structure of human IgG1 6a and IgG1
19a - The two monoclonal IgG1 antibodies
studied here have 88.7% total sequence
identity, with identical hinge regions and
differing primarily in their VH and VL domains
(Fig. 2). Our X-ray data collection involved the
measurement of 52 and 70 curves in two beam
sessions (or 520 and 700 curves if time frames
are included) (Fig. 7). This abundant data
collection enabled the use of different buffers
with two different human IgG1. The use of
three NaCl concentrations examined potential
electrostaticeffectsontheIgG1structure,while
heavy water is a known promoter of protein
self-association. By comparison, earlier
scattering studies on human IgG1 reported few
scattering and ultracentrifugation runs, or were
performed in non-physiological buffer
conditions (28,38,39,47-49). Both IgG1 6a and
IgG1 19a showed similar experimental Rg and
RXS values and the same overall length of 16 nm
(Table 1). The two IgG1 molecules also
displayed similar experimental s
0
20,w values of
6.3-6.4 S, which were indistinguishable within
error. The only change with buffer conditions
was a small increase in the Rg values in 250 mM
NaCl. The 30 best fit structures for IgG1 6a and
IgG119awerepredominantlyasymmetric,with
only one symmetric model for IgG1 6a in PBS-
137 and two symmetric models for IgG1 19a
(PBS-250) (Fig. 12). Little difference was seen
between the two IgG1 antibodies. The hinge
length is measured by the α-carbon positions of 
the flanking residues Cys
220 and Pro
238, with a
maximum possible length of 6.65 nm. The best-
fit structures gave similar hinge lengths of 2.4-
5.0 ± 0.6 nm for IgG1 6a (X-rays), 1.6-5.0 ± 0.7
nm for IgG1 19a (X-rays), and 3.2-4.9 ± 0.5 nm
for IgG1 6a (neutrons). These lengths show that
this hinge is semi-extended. The slight Rg
increase in 250 mM NaCl was best explained
by a shift from T-shaped structures in low salt
to Y-shaped structures in high salt.
The only crystal structure for an intact human
IgG is currently that for IgG1 b12 (10), and this
structure was used to model the solution
scattering data in this study. Two full-length
murine IgG crystal structures have also been
solved for IgG1 61.1.3 (11) and IgG2a Mab231
(12). These crystal structures only offer a single
view of the antibody immobilised in the crystal
lattice, in contrast to the expectation that
antibodies may display a large range of
conformations in solution. Atomistic scattering
modelling of the solution structure of IgG1
enhances our understanding of the IgG1 b12
crystal structure and yields the averaged
arrangement of the Fab and Fc fragments. IgG1
b12 was crystallised in 800 mM ammonium
sulphate and 100 mM sodium cacodylate, pH
6.5. This IgG1 crystal structure showed no
symmetry and an asymmetric arrangement of
the Fab regions, with one Fab closely packed on
top of the Fc region, and the other Fab extended
outwards. The two Cys
220-Pro
238 hinge lengths
were 3.8 nm and 3.9 nm. Both agree with the
modelled hinge lengths for IgG1 6a and IgG1
19a above. The IgG1 b12 Rg, Rxs-1 and Rxs-2
values were calculated as 5.12 nm, 2.60 nm and
1.56 nm, in agreement with the values for IgG1
6a and IgG1 19a (Table 1). The IgG1 b12 s
0
20,w
value was 6.84 S and 6.57 S from HYDRO and
HYDROPRO, in agreement with experiment
(Table 1). The d1, d2 and d3 values between the
Fab and Fc regions were also similar to those
for IgG1 6a and IgG1 19a (Fig. 13). It is
concluded that the solution structures of IgG1
6a and IgG1 19a are similar to the IgG1 b12
crystal structure.11
The comparison of IgG1 6a and IgG1 19a with
human IgG4 (15) displayed some differences.
Despite similar molecular weights, the Rg
values of human IgG1 are 0.1- 0.2 nm larger
than those for human IgG4 which has Rg, Rxs-1
and Rxs-2 values of 4.92 nm, 2.56 nm and 1.37
nm, respectively. The s
0
20,w values of IgG1 6a
and IgG1 19a are approximately 0.4 S smaller
than IgG4 whose s
0
20,w value is 6.8 S (15). Both
data sets indicate that IgG1 is more elongated
than IgG4. This is attributable to the longer
IgG1 hinge sequence, in which the upper hinge
contains three extra residues compared to IgG4
(Fig. 2).
Interaction of human IgG1 with C1q - Our
atomistic models for intact IgG1 enable the
binding of C1q to IgG1 to be assessed. As
before, molecular docking of the IgG1 Fc and
C1q crystal structures was performed to
evaluate this interaction. This structural
approach had previously shown that the rabbit
IgG interaction with C1q was sterically
allowed, but that of human IgG4 with C1q was
restricted (15,50). This C1q binding site occurs
at the top of the CH2 domain in the Fc region
near the hinge. Functionally, the reactivity of
C1q with the four human IgG subclasses
correlates with upper hinge length in the order
of IgG3 > IgG1 > IgG2 > IgG4, with IgG4 not
activating complement (3). A hingeless IgG1
antibody cannot bind or activate C1q (51).
Mutagenesis studies of the hinge modulates
C1q binding. These studies include disruption
of the inter-heavy chain disulphide covalent
bridges in the core hinge that removed the C1q
interaction, whereas substitutions in the upper
hingeincreasedC1qbinding(52).Themutation
of Leu
234 and Leu
235 to Ala residues in the lower
hinge of human IgG1 b12 also removed C1q
binding, suggesting that the lower hinge is also
important (53). A human IgG1 mutant with
Thr
223 and His
224 deleted in the upper hinge, and
Pro
227 and Pro
228 deleted in the core hinge
cannot bind or activate C1q (52). The isolated
IgG4-Fc region binds C1q although intact
human IgG4 does not, suggesting that the Fab
regions are also important for the C1q
interaction (54). In other experiments, the
mutation of human IgG1 to mimic the
disulphide bonding of IgG4 removed its
antibody-dependent cell-mediated cytotoxicity
activity (55). Reduction of the inter-heavy
chain disulphide bridges showed that these are
important for C1q binding (54). Thus the upper,
core and lower hinge contributes to C1q
binding and activation, as well as the hinge
disulphide bridges.
Docking studies were performed using a shape
complementarity method based on the
PatchDock server (36) with the best-fit IgG1 6a
and IgG1 19a models (Fig. 14A,B). Human
IgG1 residues involved in C1q binding include
Asp
270, Lys
322, Pro
329 and Pro
331 in the Fc CH2
region (56,57). Docking and molecular
dynamic simulations identified 19 C1q and 12
Fc contact residues in the IgG1-C1q complex
(Table 2 of (43)). Using these residues to guide
the docking, both Fab regions in both IgG1 6a
and IgG1 19a were seen to be positioned away
from the C1q binding site, hence enabling C1q
to bind. Steric clashes between the docked
IgG1-C1q complexes were evaluated, and
compared with those for docked IgG4-C1q
models (Fig. 15). The globular C1q head has a
molecular weight of 44.1 kDa and an
unhydrated volume of 57.1 nm
3 (21). Residues
making main-chain clashes were identified
using Swiss-PdbViewer (58), and their amino
acid volumes were summed to estimate a
notional C1q volume obstructed by the Fab-
arms. Based on all the best-fit structures, the
mean obstructed volume for IgG1 6a-C1q was
6.9nm
3, that for IgG119a-C1q was 2.1nm
3 and
that for IgG4-C1q was 19.1 nm
3. This
comparison showed that the IgG4 Fab regions
hindered C1q binding by about 3-9 times the
volume than the IgG1 Fab regions. Given that
there are two identical C1q binding sites on
either side of the Fc region, visual inspection
revealed that the other C1q binding site is
obstructed in both IgG1 and IgG4 structures.
IgG constructs with one half binding C1q and
one half not binding C1q were still able to bind
C1q, indicating that 1:1 stoichiometry of
Fc:C1q is possible (59). Therefore the
accessibility of only one C1q binding site in
IgG1 is adequate for complement activation.
Sequence differences between the IgG
subclasses may also account for the reduced
binding of C1q, with Pro
329 and Pro
331 likely to
be important for this (60,61). The strength of
Fc-C1q binding is not directly correlated to
complement activation, with IgG1 better able to
activate complement-mediated lysis than IgG3,
despite the stronger binding of IgG3 to C1q, for
example(62).ThissuggeststhatbindingofC1q
alone is not enough to activate the complement12
cascade. The Fc-C1q affinity is low with a
dissociation constant KD of approximately 10
-4
M (63,64). Localised IgG clusters may bind a
C1q hexamer through multivalent contacts to
increase the strength of the C1q-Fc interaction,
as exemplified by a hexamer configuration of
an IgG1 mutant (65).
Interaction of human IgG1 with FcγR – FcγR 
receptors are present on immune cell surfaces,
and are divided into low-affinity (subclasses
FcγRIIA/B/C  and  FcγRIIIA/B)  and  high-
affinity (subclass FcγRI only) types. Both FcγR 
typesbindIgGimmune complexes,butonly the
high-affinity  FcγR  bind  monomeric  IgG  as 
well. The binding of therapeutic antibodies to
native FcγR in vivo is sometimes exploited to
produce drug action. The affinities of the four
human IgG subclasses for specific FcγRs vary 
due to the presence of different contact residues
in the Fc fragment and the FcγRs. Human IgG1 
and IgG3 binds to all the Fcγ receptors (FcγRI, 
FcγRIIA,  FcγRIIB/C,  FcγRIIIA,  FcγRIIIB) 
whereas IgG2 and IgG4 only bind to some of
them.  For  FcγRI,  IgG1  and  IgG3  bind  most 
strongly (KA 6.5 and 6.1  10
7 M
-1
respectively), IgG4 binding is slightly weaker
(3.4  10
7 M
-1), and IgG2 displayed no
measureable binding. For the remaining FcγRII 
and FcγRIII subclasses, IgG1 and IgG3 bound 
to all the FcγRII and FcγRIII receptors with 
high KA values ranging between 1.2  10
5 M
-1
to 9.8  10
6 M
-1. In contrast, IgG4 showed low
affinity binding with KA values in the region of
2  10
7 M
-1 for  FcγRIIA/B/C  and  no 
measureable binding to FcγRIIIB. IgG2 showed 
mostly lower affinities than IgG1, IgG3 and
IgG4 for all FcγRs, including no measurable 
binding for FcγRIIIB (45). 
Our atomistic models for intact IgG1 enable the
binding of FcγR to intact IgG1 to be reviewed. 
Crystal  structures  of  the  IgG1  Fc-FcγRIIIB 
complex show that FcγR binds to the top of the 
Fc region close to the hinge (44,66). The
feasibility of the IgG1–FcγR interaction in full-
lengthIgG1wasrevealedbysuperimpositionof
our best fit IgG1 6a and IgG1 19a structures
with  the  IgG1  Fc-FcγRIIIB  crystal  structure 
(44).  FcγR  binding  is  seen  to  be  permitted 
because the Fab regions in our IgG1 models do
not  sterically  clash  with  FcγR  (Fig.  14C,D).
This is in contrast to the blocked human IgG4-
FcγRIIIB  interaction  (15)  (Fig.  15).  Other 
factors  affecting  the  strength  of  Fc-FcγR 
binding include residues present in the hinge
and CH2 domains. The IgG1 Fc residues
associated  with  FcγR  binding  include 
234LLGGP
238 of the lower hinge region (67) and
265DVSHE
269,
297NST
299 and
329PAPIE
333 of the
CH2 domain (Fig. 2) (68,44,53). Hinge
mutagenesis studies revealed that disrupting the
core hinge (CPPCP; Fig. 2) leads to reduced
IgG1  binding  to  FcγRIIIA  (52).  Sequence 
differences in the IgG subclass heavy chains
may also be relevant, with IgG1 and IgG3
possesses Leu
234 and Leu
235 in the lower hinge
region, whereas IgG2 has Val
234 and Ala
235, and
IgG4 has a Phe
234 (Fig. 2). IgG4 also has Ser
330
and Ser
331 substitutions compared to the other
IgG subclasses (68,61). These substitutions in
IgG2 and IgG4 lead to weaker FcγR binding in 
comparison to IgG1 and IgG3 which bind to all
FcγR classes.  
Steric clashes between the docked IgG1-FcγR 
complexes were also evaluated, and compared
with  those  for  the  IgG4-FcγR  models.  The 
crystal structure of a human IgG1-Fc with the
human FcRIII extracellular domains, which
have a molecular weight of 20.1 kDa and an
unhydrated volume of 25.8 nm
3 (21). As with
the IgG-C1q models above, residues making
main-chain clashes were identified using
Swiss-PdbViewer (58), and their amino acid
volumes were summed to estimate a notional
FcγR  volume  obstructed  by  the  Fab-arms. 
Based on all the best-fit structures, the mean
obstructed volume for IgG1 6a-FcγR was 6.6 
nm
3, that for IgG1 19a-FcγR was 1.6 nm
3 and
that  for  IgG4-FcγR  was  14.8  nm
3. This
comparison showed that the IgG4 Fab regions
hindered FcγR binding by about 3-9 times the 
volume than the IgG1 Fab regions.
Stability of human IgG1 - Antibody stability is
a major concern in the context of the
multibillion antibody industry where stabilities
may be compromised during manufacturing,
shipping and storage (69). The conformational
stability of IgG1 is important, as changes in the
native structure may lead to aggregation or self-
association (70). The stability of human IgG1
6a and IgG1 19a was explored here using
different buffers and temperatures. Their Rg
values increased slightly with increasing salt
concentration (Fig. 7), indicating more
elongated structures arise in higher salt
concentrations from changes in the electrostatic
interactions between surface amino acid13
residues. However, no changes were revealed
by the M1 and M2 values or s
0
20,w values (Figs.
7 and 9). No temperature dependence was
observed for IgG1 6a by neutron scattering,
withnochangesinRgandRxs,andnomovement
of the M1 and M2 peaks (Figs. 8 and 9). In
marked contrast to IgG1, human IgG4 displays
conformational instabilities in the P(r) curves
below 2 mg/ml, these being attributable to
different diffusion-collision events at different
concentrations, or to the occurrence of Fab-arm
exchange in dilute IgG4 concentrations (14,15).
Human IgG1 also showed no significant
concentration-dependent dimerization by
neutron scattering in heavy water, unlike the
noticeable dimer formation seen for IgG4.
IgG1 aggregation and self-association are
relevant also to the immune response in vivo as
well as in treatments with therapeutic
antibodies. Human serum naturally contains a
total of 1% dimeric IgG1, with less than 0.03%
of this being covalent IgG1 dimers (71).
Different oligomeric forms of human IgG1
could enhance the binding to FcγRs and C1q 
through their increased avidity as expected
(65,72). IgG1 dimers are found in therapeutic
drugs such as Epratuzumab (73), which is
currently in clinical trials, and Food and Drug
Administration-approved Palivizumab (74).
The presence of dimers and/or aggregates in
preparations of therapeutic antibodies is usually
below 1% and is regarded as an impurity (i.e.
not mediating the desired pharmacological
effect). Assessing the aggregation profile of
antibody pharmaceuticals is crucial as any
aggregates may affect its efficacy and
immunogenicity. The low amounts below 5%
of IgG1 dimer observed by sedimentation
velocity in four different buffers (Figs. 4 and 5)
showed that IgG1 6a and IgG1 19a do not
undergo significant buffer- or
concentration-dependent dimerization under
the conditions tested, especially in heavy water
which promotes self-association. The dimer
peak has an s
0
20,w value of about 9.5 S (Fig. 5),
similar to that of the rabbit IgG dimer,
suggesting that this dimer may be relatively
compact in its structure (50). Antibodies may
dimerise through the association of their Fab-
Fab and Fab-Fc regions (74), although that for
rabbit IgG was attributed to the formation of
Fab-Fab pairs (50).
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FIGURE LEGENDS
FIGURE 1. The human IgG1 domain structure. The heavy chains have VH, CH1, CH2 and CH3
domains, and the light chains have VL and CL domains. The heavy chains are connected by two Cys–
Cys disulphide bridges at Cys
226 and Cys
229. There is one N-linked oligosaccharide site at Asn
297 on
each of the CH2 domains. The hinge region between the Fab and Fc fragments is composed of 23
residues (EPKSCDKTHTCPPCPAPELLGGP) between Val
215 and Ser
239.
FIGURE 2. Sequence alignment of human IgG1. The IgG1 6a and 19a sequences were kindly
provided by Dr Bryan Smith at UCB. The IgG1 b12 sequence was taken from its crystal structure (PDB
code 1HZH). A,B, The VL and CL domains. C-E, the VH and CH1 domains and the hinge. F,G, the CH2
and CH3 domains. H, comparison of the hinge sequences from the human IgG subclasses and rabbit
IgG. For the VL, CL and VH domains, consecutive sequence numbering was used. For the CH1, CH2 and
CH3 domains, EU sequence numbering was used.
FIGURE 3. Purification of human IgG1. A, IgG1 6a and B, IgG1 19a. For each antibody, the elution
peak from a Superose 6 10/300 gel filtration column is shown on the left (mAU, milli-absorbance units)
with molecular weight markers (kDa). The non-reduced and reduced SDS-PAGE analyses are shown
on the right.
FIGURE 4. Sedimentation velocity analyses of IgG1. The experimentally observed sedimentation
boundaries for IgG1 6a in A PBS-50, PBS-137, PBS-250 in H2O and B PBS-137 in
2H2O buffers were
recorded at a rotor speed of 40,000 r.p.m. and 20°C. C IgG1 19a in PBS-137 at 20°C was also measured
at 40,000 r.p.m.. Forty boundaries (black outlines) are shown from up to 745 scans at intervals of every
e.g. 15
th scan for clarity which were fitted using SEDFIT as shown (white lines). The right panel shows
the observed s values in the corresponding size-distribution analyses c(s) revealing a monomer (M)
peak at s
0
20,w values of approximately 6.4 S for IgG1 6a and 6.3 S for IgG1 19a in H2O buffers, with a
minor dimer peak (D) at about 9 S. The observed s values in
2H2O buffers are shifted to lower s values.
FIGURE 5. Summary of IgG1 sedimentation analyses. A, the s20,w values for the monomer and dimer
peaks are shown as a function of IgG1 concentration in five buffers. B, the percentages of monomer
and dimer from integration of the c(s) analyses. For IgG1 6a, four buffers are denoted as PBS-50 (),
PBS-137 () and PBS-250 () in H2O at 20°C and in PBS-137 in
2H2O at 20°C (). For IgG1 19a,
PBS-137 at 20°C is shown as . For IgG1 6a, the average s20,w values of monomer and dimer and their
integrations are shown for PBS-50 (∙∙∙), PBS-137 (- -) and PBS-250 (―) buffers in H2O at 20°C and in
PBS-137 (
2H2O) buffer at 20°C (− ∙ −). For IgG1 19a, those for PBS-137 at 20°C (− ∙∙ −) is shown.  
FIGURE 6. X-ray and neutron Guinier Rg and Rxs analyses for IgG1.18
A, the X-ray scattering curves of IgG1 6a are shown for concentrations of 0.5, 1, 1.5 and 2 mg/ml from
bottom to top in three buffers PBS-50, PBS-137 and PBS-250 at 20°C. In PBS-137, an additional
scattering curve for 4.0 mg/ml is displayed. The filled circles represent the Q.Rg and Q.RXS ranges used
to determine the Rg and Rxs values. The Q-ranges used for the Rg values in PBS-50 and PBS-137 was
0.09-0.28 nm
-1 with the exception of 1 mg/ml IgG1 6a in PBS-50 which was 0.15-0.28 nm
-1. The Q-
range used for the Rg values in PBS-250 was 0.15-0.28 nm
-1. The Rxs-1 and Rxs-2 Q-ranges were 0.31-
0.47 nm
-1 and 0.65-1.04 nm
-1 respectively.
B, the neutron scattering curves of IgG1 6a are shown for concentrations of 2, 3 and 4 mg/ml from
bottom to top for IgG1 in PBS-137 (
2H2O) at 6°C, 20°C and 37°C. The Q range used for the Rg values
was 0.18–0.28 nm
-1 and those for the Rxs-1 and Rxs-2 values were 0.31–0.47 nm
-1 and 0.65–1.04 nm
-1,
respectively.
C, the X-ray scattering curves of IgG1 19a for concentrations of 0.22, 0.34, 0.45, 0.68, 0.90 and 1.35
mg/ml in PBS-50 buffer, 0.30, 0.47, 0.62, 0.95, 1.27 and 1.89 mg/ml in PBS-137 buffer and at 0.26,
0.41, 0.81 and 1.62 mg/ml in PBS-250 buffer at 20°C from bottom to top. The Q range used for the Rg
values was 0.09–0.28 nm
-1 for PBS-50 and PBS-137 buffers whereas a Q range of 0.15-0.28 was used
for PBS-250 buffer. The Rxs-1 and Rxs-2 Q-ranges were 0.31–0.47 nm
-1 and 0.65–1.04 nm
-1, respectively.
FIGURE 7. Concentration and temperature dependence of the X-ray and neutron Guinier
analyses.TheGuinieranalysesareshownin Fig.6.Theopensymbolsshowthevaluesfromthe Guinier
analyses, and the filled symbols show those from the P(r) analyses. A, C, the X-ray values for IgG1 6a
and IgG1 19a respectively were each measured in quadruplicate and averaged, showing the mean ± SD.
The X-ray Rg values are shown for PBS-50 ( and ), PBS-137 ( and ) and PBS-250 ( and ).
The correspondingX-ray I(0)/c, Rxs-1 and Rxs-2valuesare likewise shown. The fitted lines show the mean
values in PBS-50 (∙∙∙), PBS-137 (- -) and PBS-250 (―) buffers. For IgG1 6a, the I(0)/c values were
similar at 0.0187, 0.0158 and 0.0173 for PBS-50, PBS-137 and PBS-250 respectively. For IgG1 19a,
the I(0)/c values were also similar at 0.0178, 0.0194 and 0.0188 respectively.
B, the neutron values for IgG1 6a correspond to single measurements in PBS-137 (
2H2O). The Rg values
at 6°C ( and ), 20°C ( and ) and 37°C ( and ). The fitted lines show the mean values at
each temperature: 6°C (∙∙∙), 20°C (- -) and 37°C (―). 
FIGURE 8. X-ray and neutron distance distribution analyses P(r). The positions of the peakmaxima
M1 and M2 and the maximum length L are arrowed. A, the X-ray P(r) curves for IgG1 6a in PBS-50,
PBS-137 and PBS-250 are shown for 0.5 - 2 mg/ml. An additional curve for 4.0 mg/ml is displayed for
PBS-137. B, the neutron P(r) curves for IgG1 6a in PBS-137 at 6°C, 20°C and 37°C are shown for 2 -
4 mg/ml. C The X-ray P(r) curves of IgG1 19a for 0.22-1.35 mg/ml in PBS-50, 0.30-1.89 mg/ml in
PBS-137 and 0.26-1.62 mg/ml in PBS-250.
FIGURE 9. Summary of the X-ray and neutron P(r) analyses. A,C, the concentration dependence of
the peak maxima M1 and M2 for IgG1 6a and IgG1 19a respectively are shown for PBS-50 (), PBS-
137 () and PBS-250 (). The fitted lines are the mean values in PBS-50 (∙∙∙), PBS-137 (- -) and PBS-
250 (―) buffers. B, the neutron M1 and M2 values for IgG1 6a are shown for 6°C (), 20°C () and
37°C () in PBS-137 (
2H2O). The fitted lines are the mean values at each temperature: 6°C (∙∙∙), 20°C 
(- -) and 37°C (―). 
FIGURE 10. Constrained modelling analysis for IgG1. The 20,000 goodness-of-fit R-factors are
compared with the calculated X-ray and neutron Rg values for the IgG1 6a and IgG1 19a models. The
20,000 asymmetric and symmetric models are shown in yellow. The ten best-fit models with the lowest
R-factors are shown in green, with the best-fit model shown in pink. The experimental observed Rg
values are shown by vertical solid lines with error ranges of ± 5% shown by dashed lines. A, hydrated
X-ray models are compared with experimental X-ray data for IgG1 6a in PBS-50, PBS-137 and PBS-
250 at 20°C. B, unhydrated neutron models are compared with the experimental neutron curve for IgG1
6a in PBS-137 in
2H2O at 20°C. C, hydrated X-ray models are compared with experimental X-ray data
for IgG1 19a in PBS-50, PBS-137 and PBS-250 at 20°C.19
FIGURE 11. X-ray and neutron scattering curve fits for the best-fit IgG1 models. A, the three X-
ray fits correspond to IgG1 6a in PBS-50, PBS-137 and PBS-250 at 20°C. B, the neutron fits
corresponds to IgG1 6a at 20°C in PBS-137 in
2H2O. C, the three X-ray fits correspond to IgG1 19a in
PBS-50, PBS-137 and PBS-250 at 20°C. The experimental data are indicated by black circles and the
modelled best-fit scattering curve is indicated by the red line. The insets correspond to the experimental
and best-fit modelled P(r) curves, in which M1 and M2 are arrowed.
FIGURE 12. Sets of ten best-fit IgG1 models. The ten best-fit models from each analysis in Figs. 9
and 10 are shown superimposed upon their Fc region (red). The two Fab regions are shown in green
and blue. A, IgG1 6a in PBS-50, PBS-137 and PBS-250 (X-rays). B, IgG1 6a in PBS-137 in
2H2O
(neutrons). C, IgG1 19a in PBS-50, PBS-137 and PBS-250 (X-rays).
FIGURE 13. Distribution of the Fab-Fc distances in the human IgG1 models. The three distances
between the centre-of-mass of the twoFab and Fc regions are shown, where d1 corresponds tothe Fab1-
Fab2 separation, d2 to Fab1-Fc, and d3 to Fab2-Fc. These distances are shown in grey for the first 500
models in each of the four sets of 5,000 models after excluding the models showing steric clashes
between the Fab and Fc regions. A, the 30 best-fit X-ray models for IgG1 6a are highlighted (Fig. 10A);
B, the 10 best-fit neutron models for IgG1 6a are highlighted (Fig. 10B); C, the 30 best-fit X-ray models
for IgG1 19a are highlighted (Fig. 10C). The orange circles represent PBS-50, black circles for PBS-
137 and green circles for PBS-250.
FIGURE 14. Superimposition of the ten best-fit IgG1 models with their C1q and FcγR ligands. 
The ten X-ray best-fit IgG1 models in PBS-137 (Fig. 12A,C) are shown superimposed upon their Fc
region (red), together with the crystal structure of the C1q globular head (yellow: PDB code 1PK6) or
the crystal structure of the Fc (red)–FcγRIII (cyan) complex (PDB code 1E4K). 
A, C1q head docked with IgG1 6a.
B, C1q head docked with IgG1 19a.
C, FcγRIII-Fc superimposed with IgG1 6a. 
D, FcγRIII-Fc superimposed with IgG1 19a. 
FIGURE 15. Comparison of the human IgG1 and IgG4 complexes with their ligands. A, best-fit
model of IgG1 6a. B, best-fit model of IgG1 19a. C, best-fit model of IgG4(Ser
222). C1q is shown in
yellow, and FcγRIII is shown in cyan. 20
Table 1. Modelling searches of the X-ray and neutron scattering and sedimentation coefficient data for human IgG1
Filter Models Spheresa Rg (nm) b Rxs-1(nm) Rxs-2(nm) Dmax (nm) R-factor (%) s0
20,w (S)c
X-ray data IgG1 6a
IgG1 X-ray models None 20,000 1056-1690 2.91-7.47 0.04-3.47 0.11-2.81 n.a. n.a. n.a.
IgG1 b12
(PDB ID: 1HZH) n.a. n.a. 1618 5.12 2.60 1.56 n.a. n.a. 6.84;
6.57
X-ray fit, 2 mg/ml,
PBS-50
Rg, Rxs,
spheres 10 1599-1634 5.09-5.26 2.56-2.66 1.29-1.42 n.a. 3.0 6.67-6.77;
6.39-6.58
Experimental data n.a. n.a. n.a. 5.21 ± 0.03;
5.25 ± 0.05 2.57 ± 0.04 1.42 ± 0.06 16 n.a. 6.42
X-ray fit, 4 mg/ml,
PBS-137
Rg, Rxs,
spheres 10 1600-1635 5.14-5.26 2.58-2.68 1.37-1.46 n.a. 3.1 6.67-6.76;
6.37-6.54
Experimental data n.a. n.a. n.a. 5.20 ± 0.06;
5.23 ± 0.03 2.61 ± 0.02 1.42 ± 0.01 16 n.a. 6.42
X-ray fit, 2 mg/ml,
PBS-250
Rg, Rxs,
spheres 10 1594-1624 5.00-5.18 2.61-2.71 1.38-1.48 n.a. 3.0-3.1 6.70-6.82;
6.47-6.73
Experimental data n.a. n.a. n.a. 5.28 ± 0.08;
5.31 ± 0.06 2.57 ± 0.05 1.47 ± 0.04 16 n.a. 6.35
Neutron data IgG1 6a
IgG1 neutron models None 20,000 862-1284 2.77-6.27 0.05-3.00 0.22-2.49 n.a. n.a. n.a.
IgG1 b12
(PDB ID: 1HZH) n.a. n.a. 1229 4.79 2.32 1.41 n.a. n.a. 6.84;
6.57
Neutron fit, 4 mg/ml,
PBS-137, 20°C
Rg, Rxs,
spheres 10 1213-1242 4.93-4.98 2.48-2.56 1.17-1.24 n.a. 2.6-2.7 7.09-7.41;
6.29-6.47
Experimental data n.a. n.a. n.a. 5.18; 5.16 2.45 ± 0.01 1.21 ± 0.01 16 n.a. 6.47
X-ray data IgG1 19a
X-ray fit, 1.4 mg/ml,
PBS-50
Rg, Rxs,
spheres 10 1606-1642 5.11-5.18 2.55-2.63 1.51-1.58 n.a. 2.8-2.9 6.69-6.78;
6.37-6.66
Experimental data n.a. n.a. n.a. 5.13 ± 0.03;
5.17 ± 0.02 2.61 ± 0.07 1.50 ± 0.04 15 n.a. n.m.
X-ray fit, 1.9 mg/ml,
PBS-137
Rg, Rxs,
spheres 10 1581-1625 4.92-5.10 2.56-2.65 1.41-1.52 n.a. 3.6-3.7 6.79-6.90;
6.53-6.6821
Experimental data n.a. n.a. n.a. 4.96;
5.15 2.53 ± 0.02 1.45 ± 0.01 16 n.a. 6.34
X-ray fit, 1.6 mg/ml,
PBS-250
Rg, Rxs,
spheres 10 1618-1655 5.08-5.25, 2.65-2.73 1.43-1.52 n.a. 3.1-3.2 6.63-6.76;
6.40-6.60
Experimental data n.a. n.a. n.a. 5.29 ± 0.04;
5.32 ± 0.04 2.63 ± 0.01 1.49 ± 0.01 16 n.a. n.m.
a The optimum number of hydrated (X-ray) and and unhydrated (neutron) spheres predicted from the sequence was 1607 and 1220, respectively.
b The first experimental value is from the Guinier Rg analysis (Fig. 6), and the second one is from the GNOM P(r) analysis (Fig. 8).
c The first modelled value corresponds to that from HYDRO, and the second one isis that from HYDROPRO
n.a., not applicable
n.m., not measured22
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